Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17242316 | 0.83 | MEN1 (0.54) | KMT2AMEN1KDM4ELMNARAB9A | |
| SCHEMBL23629467 | 0.82 | SLC22A6 (0.60) | KMT2AMEN1KDM4ELMNARAB9A | |
| SCHEMBL2001612 | 0.79 | SLC22A6 (0.65) | KMT2AMEN1KDM4ELMNAMAPT | |
| SCHEMBL28337310 | 0.76 | GPR84 (0.64) | KMT2AMEN1KDM4ELMNARAB9A | |
| SCHEMBL2347588 | 0.75 | SLC22A6 (0.41) | KMT2AMEN1NR4A2ALDH1A1GPR84 | |
| SCHEMBL4489769 | 0.75 | NR4A2 (0.57) | KMT2AMEN1KDM4ELMNARAB9A | |
| SCHEMBL27898848 | 0.75 | HTR1D (0.60) | KMT2AMEN1KDM4ERAB9AALDH1A1 | |
| SCHEMBL8883632 | 0.74 | MTNR1A (0.54) | KMT2AMEN1KDM4ELMNARAB9A | |
| SCHEMBL14665122 | 0.73 | KDM4E (0.75) | KMT2AMEN1KDM4ERAB9AMAPT | |
| SCHEMBL2834218 | 0.73 | NR4A2 (0.75) | KMT2AMEN1KDM4ELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819697-B1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-8008320-B2 | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors | Johannes Gutenberg-Universitatis (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1819697-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006061212-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | FLT4, KDR, FLT1 | KMT2A 2012/4885MEN1 626/4885KDM4E 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.